DMN:FRA
Diamyd Medical AB
0,063 €
0,00%
(0,00) 1D
12 նոյ, 08:01:47 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
143,16 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
143,16 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
USA Today
·
1 ժամ առաջ
Mobilicom (NASDAQ: MOB) Establishes First U.S. Manufacturing Operations in Arizona to Expand Cybersecure Datalink Production
www.foreignpolicyjournal.com
·
13 րոպե առաջ
AST SpaceMobile (NASDAQ: ASTS) Burns Through Cash At A Pace That Dwarfs Its Revenue Growth, Raising Questions About Its Lofty Valuation
Yahoo Finance
·
8 րոպե առաջ
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
TradingView
·
3 ժամ առաջ
Nine Listings Transfer to the NYSE in 2026 Amounting to $500B in Market Cap
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB